Ongoing Clinical Trials for Staphylococcal Bacteraemia
There are currently 5 clinical trials investigating treatments for staphylococcal bacteraemia, a serious blood infection caused by Staphylococcus aureus bacteria. These studies are testing different antibiotics and treatment durations across several European countries, including Sweden, the Netherlands, Germany, and Denmark. The trials aim to improve treatment effectiveness while potentially reducing therapy duration and side effects for patients.
Clinical trial locations
- Denmark
- Germany
- Netherlands
- Sweden
- Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients
- Study on How Kidney Function Estimates Help Adjust Cloxacillin Dosing in Patients with Staphylococcus aureus Bacteremia
- Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia
Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients
This Swedish trial is comparing two antibiotics, benzylpenicillin and cloxacillin, for treating bloodstream infections caused by Staphylococcus aureus bacteria that are sensitive to penicillin. Both medications are given directly into the vein through an injection or infusion.
Who can participate: Adults over 18 years old with a confirmed penicillin-susceptible Staphylococcus aureus blood infection who can provide informed consent. The trial is open to both men and women, including those who may need extra care or protection.
Who cannot participate: People with allergies to penicillin or cloxacillin, those with a history of severe allergic reactions to antibiotics, pregnant or breastfeeding women, patients with liver or kidney problems, those currently in another clinical trial, people with weakened immune systems, patients who recently had a heart attack or stroke, those with uncontrolled diabetes, people with a history of drug or alcohol abuse, and anyone unable to follow study procedures.
What the trial aims to discover: The study will monitor patients for up to seven days of treatment and then for 90 days afterward to determine if patients remain alive and free of complications. Success means no return of the infection and no need to change antibiotics due to side effects or treatment failure. This research will help determine which of these two antibiotics is more effective for this type of infection.
Investigational drugs: Benzylpenicillin works by stopping bacteria from building their cell walls, which destroys them. Cloxacillin is a special type of penicillin designed to work against certain resistant bacteria, and it also works by preventing bacteria from making their protective cell walls.
Study on How Kidney Function Estimates Help Adjust Cloxacillin Dosing in Patients with Staphylococcus aureus Bacteremia
This Swedish study investigates whether measuring kidney function can help doctors adjust the dose of cloxacillin for patients with Staphylococcus aureus blood infections. The trial uses therapeutic drug monitoring to check if drug levels in the blood are safe and effective.
Who can participate: Adults aged 18 years or older who have a positive blood test for Staphylococcus aureus taken within 72 hours before joining, have started or will start cloxacillin treatment within 72 hours, and have provided written consent.
Who cannot participate: People younger than 18 or older than 65 years, and those considered part of a vulnerable population who cannot make decisions for themselves.
What the trial aims to discover: The study monitors patients on days 2 and 7 with blood tests to measure cloxacillin levels and kidney function. Researchers want to see if kidney function measurements can predict which patients need dose adjustments. Daily monitoring checks for signs of kidney damage and nervous system effects like confusion or seizures. The goal is to ensure the antibiotic dose is both safe and effective for each patient’s kidney function level.
Investigational drug: Cloxacillin is administered through a vein and belongs to a group of antibiotics called penicillinase-resistant penicillins. It kills bacteria by preventing them from forming their protective cell walls.
Study on Reducing Antibiotic Duration for Patients with Complicated Staphylococcus aureus Bacteremia Using Cefazolin Sodium, Flucloxacillin Sodium Monohydrate, and Clindamycin
This trial in the Netherlands is examining whether four weeks of antibiotic treatment is as effective as the traditional six-week treatment for patients with complicated Staphylococcus aureus blood infections who have responded well to initial therapy.
Who can participate: Adults with methicillin-sensitive complicated blood infections showing signs of deep-seated infection such as heart valve infection, spine infection, joint infection, blood vessel infection, or abscesses. Patients must have at least one positive blood test and certain risk factors, including infections acquired outside hospitals, delays in starting proper treatment, prolonged fever, or unknown infection source. Good response to initial treatment is required, including negative blood tests by day 8, reduced inflammation markers, and no fever between 7 and 14 days of treatment.
Who cannot participate: Patients who haven’t responded well to initial treatment and those from vulnerable populations.
What the trial aims to discover: After initial treatment, patients are randomly assigned to receive either 4 or 6 weeks of total antibiotic treatment. They are then monitored for 180 days to assess if they remain alive without disease relapse. The trial aims to determine if shorter treatment can be equally effective, potentially reducing treatment duration and side effects.
Investigational drugs: The trial uses antibiotics including cefazolin sodium, flucloxacillin sodium monohydrate, and clindamycin, all of which work by fighting bacterial infections through different mechanisms that stop bacteria from growing or kill them directly.
Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia
This multi-country trial, taking place in Germany, the Netherlands, and Sweden, is studying various antibiotic treatments to see which are most effective at improving 90-day survival rates for patients with Staphylococcus aureus blood infections.
Who can participate: Adults admitted to participating hospitals who have at least one blood test showing Staphylococcus aureus bacteria. Both men and women can participate.
Who cannot participate: Patients with different types of infections, those under 18 or over 65 years old, pregnant or breastfeeding women, people with severe allergies to study medications, those currently in another trial, patients with weakened immune systems, those who recently had heart attacks or strokes, people with uncontrolled diabetes, patients with histories of drug or alcohol abuse, and anyone unable to follow study procedures.
What the trial aims to discover: Participants receive one of many antibiotics including rifampicin, doxycycline, co-trimoxazole, cefazolin, flucloxacillin, daptomycin, benzylpenicillin sodium, amoxicillin, levofloxacin, clindamycin, cefalexin, moxifloxacin, linezolid, or vancomycin. Patients are monitored closely throughout the 90-day study period to assess survival rates, hospital stay length, and recovery progress. The study will provide valuable information on which antibiotics work best for this serious infection.
Investigational drugs: The trial tests multiple antibiotics that work by either stopping bacterial growth or killing bacteria. Key medications include vancomycin, daptomycin, linezolid, and ceftaroline, each with different mechanisms for fighting bacterial infections.
Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection
This Danish trial compares 7-day versus 14-day antibiotic treatment courses for uncomplicated Staphylococcus aureus blood infections to determine if shorter treatment is equally effective.
Who can participate: Adults 18 years or older with a positive blood test for Staphylococcus aureus who started effective antibiotic treatment within 12 hours of the first positive test. Patients must have a body temperature below 37.8°C at enrollment and a follow-up blood test showing no bacteria between 48 to 120 hours after initial diagnosis.
Who cannot participate: Patients with different types of infections and those from vulnerable populations requiring special protection or care.
What the trial aims to discover: Participants are randomly assigned to receive either 7 or 14 days of antibiotic treatment. They are monitored for 90 days to check for infection recurrence or health issues. The study examines whether shorter treatment reduces side effects and healthcare costs while remaining as effective as longer treatment. Researchers evaluate survival rates, treatment failure, and adverse events to determine optimal treatment duration.
Investigational drugs: Multiple antibiotics are being tested, including clarithromycin, meropenem, ceftriaxone, cefotaxime, piperacillin/tazobactam, vancomycin, dicloxacillin, flucloxacillin, linezolid, clindamycin, levofloxacin, moxifloxacin, amikacin, gentamicin, benzylpenicillin, cloxacillin, and daptomycin. These medications work by either preventing bacteria from building cell walls or stopping their protein production, ultimately killing the bacteria.
Summary
The five ongoing clinical trials for staphylococcal bacteraemia reflect a strong focus on optimizing antibiotic treatment across multiple European countries. Sweden hosts the most trials with three studies, while the Netherlands has two, and Denmark and Germany each have one. A notable multi-country trial spans Germany, the Netherlands, and Sweden.
A key theme across these studies is the investigation of treatment duration. Multiple trials are examining whether shorter antibiotic courses can be as effective as traditional longer treatments, which could reduce side effects and healthcare costs. The trials also focus on personalized medicine approaches, such as adjusting doses based on kidney function and identifying which patients respond best to specific antibiotics.
Cloxacillin appears frequently across the trials, reflecting its importance in treating penicillin-susceptible infections. Other commonly studied antibiotics include vancomycin, benzylpenicillin, and various combinations of medications. The studies distinguish between complicated and uncomplicated infections, recognizing that different patient groups may require different treatment approaches.
All trials emphasize patient safety through careful monitoring for side effects, particularly kidney damage and nervous system effects. The research aims to provide evidence-based guidance for treating this serious infection more effectively while minimizing risks to patients.
